Inhibitors of lactate dehydrogenase isoforms and their therapeutic potentials

Current Medicinal Chemistry

Volumn 17, Issue 7, 2010, Pages 672-697

  Granchi, C ^a   Bertini, S ^a   Macchia, M ^a   Minutolo, F ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Cancer; Enzyme; Glycolysis; Inhibitors; Lactate dehydrogenase; Malaria; Plasmodium; Warburg effect

Indexed keywords

ADENOSINE TRIPHOSPHATE; ENZYME INHIBITOR; LACTATE DEHYDROGENASE; LACTATE DEHYDROGENASE INHIBITOR; UNCLASSIFIED DRUG;

ANAEROBIC GLYCOLYSIS; CANCER INHIBITION; CITRIC ACID CYCLE; DRUG ACTIVITY; DRUG TARGETING; ENERGY YIELD; ENZYME INHIBITION; HUMAN; MALARIA; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PLASMODIUM FALCIPARUM; PROTEIN PHOSPHORYLATION; REVIEW; TUMOR GROWTH;

ANTIMALARIALS; ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; GLYCOLYSIS; HUMANS; L-LACTATE DEHYDROGENASE; MALARIA; NEOPLASMS; PLASMODIUM FALCIPARUM; PROTEIN ISOFORMS; PROTOZOAN PROTEINS;

EID: 77950643062     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710790416263     Document Type: Review

References (85)

1. White, J.L.; Hackert, M.L.; Buehner, M.; Adams, M.J.; Ford, G.C.; Lentz, P.J. Jr.; Smiley, I.E.; Steindel, S.J.; Rossmann, M.G. A comparison of the structures of apo dogfish M4 lactate dehydrogenase and its ternary complexes. J. Mol. Biol., 1976, 102, 759-779.
2. Grau, U.M.; Trommer, W.E.; Rossmann, M.G. Structure of the active ternary complex of pig heart lactate dehydrogenase with S-lac-NAD at 2.7 A resolution. J. Mol. Biol., 1981, 151, 289-307.
3. Piontek, K.; Chakrabarti, P.; Schär, H.P.; Rossmann, M.G.; Zuber, H. Structure determination and refinement of Bacillus stearothermophilus lactate dehydrogenase. Proteins, 1990, 7, 74-92. (Pubitemid 20102604)
4. Iwata, S.; Ohta, T. Molecular basis of allosteric activation of bacterial L-lactate dehydrogenase. J. Mol. Biol., 1993, 230, 21-27. (Pubitemid 23093544)
5. Dunn, C.R.; Banfield, M.J.; Barker, J.J.; Higham, C.W.; Moreton, K.M.; Turgut-Balik, D.; Brady, R.L.; Holbrook, J.J. The structure of lactate dehydrogenase from Plasmodium falciparum reveals a new target for anti-malarial design. Nat. Struct. Biol., 1996, 3, 912-915.
6. Read, J.A.; Winter, V.J.; Eszes, C.M.; Sessions, R.B.; Brady, R.L. Structural basis for altered activity of M- and H-isozyme forms of human lactate dehydrogenase. Proteins, 2001, 43, 175-185.
7. Everse, J.; Kaplan, N.O. Lactate dehydrogenases: structure and function. Adv. Enzymol. Relat. Areas Mol. Biol., 1973, 37, 61-133.
8. Markert, C.L. Lactate dehydrogenase. Biochemistry and function of lactate dehydrogenase. Cell. Biochem. Funct., 1984, 2, 131-134.
9. Banga, I.; Szent-Gyorgyi, A.; Vargha, L. The coenzyme of lactic acid oxidation. Z. physiol. Chem., 1932, 210, 228-235.
10. Straub, F.B. Crystalline lactic dehydrogenase from heart muscle. Biochem. J., 1940, 34, 483-486.
11. Kopperschläger, G.; Kirchberger, J. Methods for the separation of lactate dehydrogenases and clinical significance of the enzyme. J. Chromatogr. B Biomed. Appl., 1996, 684, 25-49. (Pubitemid 26340381)
12. Cahn, R.D.; Zwilling, E.; Kaplan, N.O.; Levine, L. Nature and development of lactic dehydrogenases: the two major types of this enzyme form molecular hybrids which change in makeup during development. Science, 1962, 136, 962-969.
13. Royer, R.E.; Deck, L.M.; Campos, N.M.; Hunsaker, L.A.; Vander Jagt, D.L. Biologically active derivatives of gossypol: synthesis and antimalarial activities of peri-acylated gossylic nitriles. J. Med. Chem., 1986, 29, 1799-1801.
14. Deck, L.M.; Royer, R.E.; Chamblee, B.B.; Hernandez, V.M.; Malone, R.R.; Torres, J.E.; Hunsaker, L.A.; Piper, R.C.; Makler, M.T.; Vander Jagt D.L. Selective inhibitors of human lactate dehydrogenases and lactate dehydrogenase from the malarial parasite Plasmodium falciparum. J. Med. Chem., 1998, 41, 3879-3887.
15. Choi, S.R.; Pradhan, A.; Hammond, N.L.; Chittiboyina, A.G.; Tekwani, B.L.; Avery, M.A. Design, synthesis, and biological evaluation of Plasmodium falciparum lactate dehydrogenase inhibitors. J. Med. Chem., 2007, 50, 3841-3850. (Pubitemid 47292047)
16. Cameron, A.; Read, J.; Tranter, R.; Winter, V.J.; Sessions, R.B.; Brady, R.L.; Vivas, L.; Easton, A.; Kendrick, H.; Croft, S.L.; Barros, D.; Lavandera, J.L.; Martin, J.J.; Risco, F.; García-Ochoa, S.; Gamo, F.J.; Sanz, L.; Leon, L.; Ruiz, J.R.; Gabarró, R.; Mallo, A.; Gómez de las Heras, F. Identification and activity of a series of azole-based compounds with lactate dehydrogenase-directed antimalarial activity. J. Biol. Chem., 2004, 279, 31429-31439. (Pubitemid 39037810)
17. Choi, S.R.; Beeler, A.B.; Pradhan, A.; Watkins, E.B.; Rimoldi, J.M.; Tekwani, B.; Avery, M.A. Generation of oxamic acid libraries: antimalarials and inhibitors of Plasmodium falciparum lactate dehydrogenase. J. Comb. Chem., 2007, 9, 292-300.
18. Fantin, V.R.; St-Pierre, J.; Leder, P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell., 2006, 9, 425-434. (Pubitemid 43832190)
19. Neilands, J.B. The purity of crystalline lactic dehydrogenase. Science, 1952, 115, 143-144.
20. Yu, Y.; Deck, J.A.; Hunsaker, L.A.; Deck, L.M.; Royer, R.E.; Goldberg, E.; Vander Jagt, D.L. Selective active site inhibitors of human lactate dehydrogenases A4, B4, and C4. Biochem. Pharmacol. 2001, 62, 81-89.
21. 4 at 2.9 Å resolution. J. Biol. Chem. 1979, 254, 7611-7620.
22. Hogrefe, H. H.; Griffith, J. P.; Rossmann, M. G.; Goldberg, E. Characterization of the antigenic sites on the refined 3-Å resolution structure of mouse testicular lactate dehydrogenase C4. J. Biol. Chem. 1987, 262, 13155-13162.
23. Brooks, G.A.; Dubouchaud, H.; Brown, M.; Sicurello, J.P.; Butz, C.E. Role of mitochondrial lactate dehydrogenase and lactate oxidation in the intracellular lactate shuttle. Proc. Natl. Acad. Sci. USA, 1999, 96, 1129-1134.
24. Van Hall, G. Lactate as a fuel for mitochondrial respiration. Acta Physiol. Scand., 2000, 168, 643-656.
25. Holbrook, J. J.; Liljas, A.; Steindel, S. J.; Rossmann, M. G. Lactate Dehydrogenase. In Enzymes, 3rd Ed. Boyer, P.D. Ed.; Academic Press: New York, 1975, Vol. 11, pp. 191-292.
26. Bellamacina, C.R. The nicotinamide dinucleotide binding motif: a comparison of nucleotide binding proteins. FASEB J., 1996, 10, 1257-1269.
27. Thomlinson, R.H.; Gray, L.H. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br. J. Cancer, 1955, 9, 539-549.
28. 2 tension measurements. Cancer Res., 1991, 51, 3316-3322.
29. Vaupel, P.; Mayer, A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev., 2007, 26, 225-239. (Pubitemid 47101660)
30. Sørensen, B.S.; Alsner, J.; Overgaard, J.; Horsman, M.R. Hypoxia induced expression of endogenous markers in vitro is highly influenced by pH. Radiother. Oncol., 2007, 83, 362-366. (Pubitemid 46907983)
31. Sørensen, B.S.; Hao, J.; Overgaard, J.; Vorum, H.; Honore, B.; Alsner, J.; Horsman, M.R. Influence of oxygen concentration and pH on expression of hypoxia induced genes. Radiother. Oncol., 2005, 76, 187-193. (Pubitemid 41725446)
32. Hsu, P.P.; Sabatini, D.M. Cancer cell metabolism: Warburg and beyond. Cell, 2008, 134, 703-707.
33. Xie, H.; Valera, V. A.; Merino, M. J.; Amato, A. M.; Signoretti, S.; Linehan, W. M.; Sukhatme, V. P.; Seth, P. LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer. Mol. Cancer Ther. 2009, 8, 626-635.
34. Marin-Hernandez, A.; Gallardo-Perez, J. C.; Ralph, S. J.; Rodriguez-Enriquez, S.; Moreno-Sanchez, R. HIF-1α modulates energy metabolism in cancer cells by inducing over-expression of specific glycolytic isoforms. Mini-Rev. Med. Chem., 2009, 9, 1084-1101.
35. Kroemer, G.; Pouyssegur, J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell, 2008, 13, 472-482. (Pubitemid 351766797)
36. Younes, M.; Lechago, L.V.; Lechago, J. Overexpression of the human erythrocyte glucose transporter occurs as a late event in human colorectal carcinogenesis and is associated with an in creased incidence of lymph node metastases. Clin. Cancer Res., 1996, 2, 1151-1154. (Pubitemid 26238445)
37. 18F-FDG PET detection of colonic adenomas. J. Nucl. Med., 2001, 42, 989-992.
38. Warburg, O. On the origin of cancer cells. Science, 1956, 123, 309-314.
39. Gatenby, R.A.; Gillies, R.J. Why do cancers have high aerobic glycolysis? Nat. Rev. Cancer, 2004, 4, 891-899.
40. Gray, L.H.; Conger, A.D.; Ebert, M.; Hornsey, S.; Scott, O.C. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br. J. Radiol., 1953, 26, 638-648.
41. Moeller, B.J.; Richardson, R.A.; Dewhirst, M.W. Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment. Cancer Metastasis Rev., 2007, 26, 241-248. (Pubitemid 47101661)
42. Brown, J.M.; Wilson, W.R. Exploiting tumour hypoxia in cancer treatment. Nat. Rev. Cancer, 2004, 4, 437-447.
43. Lopez-Lazaro, M. Role of oxygen in cancer: looking beyond hypoxia. Anti-Cancer Agents Med. Chem. 2009, 9, 517-525.
44. Iessi, E.; Marino, M. L.; Lozupone, F.; Fais, S.; De Milito, A. Tumor acidity and malignancy: novel aspects in the design of antitumor therapy. Cancer Ther., 2008, 6, 55-66.
45. Sullivan, R.; Graham, C.H. Hypoxia-driven selection of the metastatic phenotype. Cancer Metastasis Rev., 2007, 26, 319-331.
46. Chen, Y.; Hu, L. Design of anticancer prodrugs for reductive activation. Med. Res. Rev., 2009, 29, 29-64.
47. Brown, J.M. Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies. Mol. Med. Today, 2000, 6, 157-162.
48. Giaccia, A. J.; Siim, B.G.; Johnson, R.S. HIF-1 as a target for drug development. Nat. Rev. Drug Discov., 2003, 2, 803-811.
49. López-Lázaro, M. The Warburg effect: why and how do cancer cells activate glycolysis in the presence of oxygen? Anticancer Agents Med. Chem., 2008, 8, 305-312. (Pubitemid 351761435)
50. Scatena, R.; Bottoni, P.; Pontoglio, A.; Mastrototaro, L.; Giardina, B. Glycolytic enzyme inhibitors in cancer treatment. Expert Opin. Investig. Drugs, 2008, 17, 1533-1545.
51. Koukourakis, M.I.; Giatromanolaki, A.; Sivridis, E.; Bougioukas, G.; Didilis, V.; Gatter, K.C.; Harris, A.L.; Tumour and Angiogenesis Research Group. Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis. Br. J. Cancer, 2003, 89, 877-885.
52. Koukourakis, M.I.; Giatromanolaki, A.; Sivridis, E.; Tumour and Angiogenesis Research Group. Lactate dehydrogenase isoenzymes 1 and 5: differential expression by neoplastic and stromal cells in non-small cell lung cancer and other epithelial malignant tumors. Tumour Biol., 2003, 24, 199-202.
53. Pathak, C.; Jaiswal, Y. K.; Vinayak, M. Modulation in the activity of lactate dehydrogenase and level of c-Myc and c-Fos by modified base queuine in cancer. Cancer Biol. Ther. 2008, 7, 85-91. (Pubitemid 351590458)
54. Kanno, T.; Sudo, K.; Maekawa, M.; Nishimura, Y.; Ukita, M.; Fukutake, K. Lactate dehydrogenase M-subunit deficiency: a new type of hereditary exertional myopathy. Clin. Chim. Acta, 1988, 173, 89-98. (Pubitemid 18077508)
55. Miyajima, H.; Takahashi, Y.; Suzuki, M.; Shimizu, T.; Kaneko, E. Molecular characterization of gene expression in human lactate dehydrogenase-A deficiency. Neurology, 1993, 43, 1414-1419. (Pubitemid 23213820)
56. Lang-Unnasch, N.; Murphy, A.D. Metabolic changes of the malaria parasite during the transition from the human to the mosquito host. Annu. Rev. Microbiol., 1998, 52, 561-590.
57. Sherman, I.W. Biochemistry of Plasmodium (malarial parasites). Microbiol. Rev., 1979, 43, 453-495.
58. Vander Jagt, D.L.; Hunsaker, L.A.; Heidrich, J.E. Partial purification and characterization of lactate dehydrogenase from Plasmodium falciparum. Mol. Biochem. Parasitol., 1981, 4, 255-264.
59. Bzik, D.J.; Fox, B.A.; Gonyer, K. Expression of Plasmodium falciparum lactate dehydrogenase in Escherichia coli. Mol. Biochem. Parasitol., 1993, 59, 155-166. (Pubitemid 23128567)
60. Gomez, M.S.; Piper, R.C.; Hunsaker, L.A.; Royer, R.E.; Deck, L.M.; Makler, M.T.; Vander Jagt, D.L. Substrate and cofactor specificity and selective inhibition of lactate dehydrogenase from the malarial parasite P. falciparum. Mol. Biochem. Parasitol., 1997, 90, 235-246. (Pubitemid 28044391)
61. Brady, R.L.; Cameron, A. Structure-based approaches to the development of novel anti-malarials. Curr. Drug Targets, 2004, 5, 137-149. (Pubitemid 38279412)
62. Brown, W.M.; Yowell, C.A.; Hoard, A.; Vander Jagt, T.A.; Hunsaker, L.A.; Deck, L.M.; Royer, R.E.; Piper, R.C.; Dame, J.B.; Makler, M.T.; Vander Jagt, D.L. Comparative structural analysis and kinetic properties of lactate dehydrogenases from the four species of human malarial parasites. Biochemistry, 2004, 43, 6219-6229. (Pubitemid 38669490)
63. Jaroszewski, J.W.; Strøm-Hansen, T.; Hansen, S.H.; Thastrup, O.; Kofod, H. On the botanical distribution of chiral forms of gossypol. Planta Med., 1992, 58, 454-458.
64. Adams, R.; Geissman, T.A.; Edwards, J.D. Gossypol, a pigment of cottonseed. Chem. Rev., 1960, 60, 555-574.
65. Dodou, K. Investigations on gossypol: past and present developments. Expert Opin. Investig. Drugs, 2005, 14, 1419-1434. (Pubitemid 41601456)
66. Wu, D. An overview of the clinical pharmacology and therapeutic potential of gossypol as a male contraceptive agent and in gynaecological disease. Drugs, 1989, 38, 333-341. (Pubitemid 19234434)
67. National Coordinating Group on Male Antifertility Agents. Gossypol - a new antifertility agent for males. Chin. Med. J., 1978, 4, 417-428.
68. Razakantoanina, V.; Nguyen Kim, P.P.; Jaureguiberry, G. Antimalarial activity of new gossypol derivatives. Parasitol. Res., 2000, 86, 665-668.
69. Qian, S.Z.; Jing, G.W.; Wu, X.Y.; Xu, Y.; Li, Y.Q.; Zhou, Z.H. Gossypol related hypokalemia. Clinicopharmacologic studies. Chin. Med. J., 1980, 93, 477-482.
70. Yu, Z.H.; Chan, H.C. Gossypol and hypokalemia: a critical review. Adv. Contracept. Deliv. Syst., 1994, 10, 23-33.
71. Yu, Z.H.; Chan, H.C. Gossypol as a male antifertility agent - why studies should have been continued. Int. J. Androl., 1998, 21, 2-7. (Pubitemid 28230973)
72. Vander Jagt, D.L.; Deck, L.M.; Royer, R.E. Gossypol: prototype of inhibitors targeted to dinucleotide folds. Curr. Med. Chem., 2000, 7, 479-498.
73. Lee, C.Y.; Moon, Y.S.; Yuan, J.H.; Chen, A.F. Enzyme inactivation and inhibition by gossypol. Mol. Cell. Biochem., 1982, 47, 65-70.
74. Coyle, T.; Levante, S.; Shetler, M.; Winfield, J. In vitro and in vivo cytotoxicity of gossypol against central nervous system tumor cell lines. J. Neurooncol., 1994, 19, 25-35. (Pubitemid 24258538)
75. Deck, L.M.; Vander Jagt, D.L.; Royer, R.E. Gossypol and derivatives: a new class of aldose reductase inhibitors. J. Med. Chem., 1991, 34, 3301-3305.
76. Royer, R.E.; Deck, L.M.; Vander Jagt, T.J.; Martinez, F.J.; Mills, R.G.; Young, S.A.; Vander Jagt, D.L. Synthesis and anti-HIV activity of 1,1'-dideoxygossypol and related compounds. J. Med. Chem., 1995, 38, 2427-2432.
77. Royer, R.E.; Mills, R.G.; Deck, L.M.; Mertz, G.J.; Vander Jagt, D.L. Inhibition of human immunodeficiency virus type I replication by derivatives of gossypol. Pharmacol. Res., 1991, 24, 407-412.
78. Dando, C.; Schroeder, E.R.; Hunsaker, L.A.; Deck, L.M.; Royer, R.E.; Zhou, X.; Parmley, S.F.; Vander Jagt, D.L. The kinetic properties and sensitivities to inhibitors of lactate dehydrogenases (LDH1 and LDH2) from Toxoplasma gondii: comparisons with pLDH from Plasmodium falciparum. Mol. Biochem. Parasitol., 2001, 118, 23-32. (Pubitemid 33043817)
79. Conners, R.; Schambach, F.; Read, J.; Cameron, A.; Sessions, R.B.; Vivas, L.; Easton, A.; Croft, S.L.; Brady, R.L. Mapping the binding site for gossypol-like inhibitors of Plasmodium falciparum lactate dehydrogenase. Mol. Biochem. Parasitol., 2005, 142, 137-148.
80. Sheffield, D.J.; Wooldridge, K.R. Synthesis of some 4-pyridylpyruvic acids as potential lactate dehydrogenase inhibitors. J. Chem. Soc. [Perkin 1], 1972, 20, 2506-2509.
81. Kato, Y.; Asano, Y.; Cooper, A.J.L. 3-Hydroxy-2-oxo-1-oxaspiro[4.5]-dec- 3-ene, a new inhibitor of lactate dehydrogenase. Tetr. Lett., 1995, 36, 4809-4812.
82. Mishra, L.; Singh, A.K.; Trigun, S.K.; Singh, S.K.; Pandey, S.M. Anti-HIV and cytotoxic ruthenium(II) complexes containing flavones: biochemical evaluation in mice. Indian J. Exp. Biol., 2004, 42, 660-666.
83. Trigun, S.K.; Surendra, K.; Koiri, R.K.; Mishra, L.; Dubey, S.K.; Singh, S.; Pandey, P. Ruthenium complex as enzyme modulator: modulation of lactate dehydrogenase by a novel ruthenium(II) complex containing 4-Carboxy N-ethylbenzamide as a ligand. Curr. Enz. Inhib., 2007, 3, 243-353. (Pubitemid 47232954)
84. Koiri, R.K.; Trigun, S.K.; Dubey, S.K.; Singh, S.; Mishra, L. Metal Cu(II) and Zn(II) bipyridyls as inhibitors of lactate dehydrogenase. Biometals, 2008, 21, 117-126.
85. Mazzio, E.; Soliman, K. WO2006017494